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Michael D. Schaller‡i**
From the ‡Department of Cell Biology and Anatomy, School of Medicine, the §Department of Prosthodontics, School of
Dentistry, and iLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina 27599 and ¶McGill Cancer Centre, McGill University, Montreal, Quebec H3G 1Y6, Canada
Tyrosine phosphorylation of focal adhesion-associ-
ated proteins may be involved in the regulation of the
cytoskeleton and in the control of signals for growth and
survival. The focal adhesion kinase (FAK) functions in
regulating tyrosine phosphorylation of several of these
proteins, including paxillin, tensin, and p130cas. Protein-
tyrosine phosphatases, the counterparts of protein-ty-
rosine kinases, also presumably regulate phosphoryla-
tion of these proteins. We have tested the hypothesis
that FAK intimately associates with a protein-tyrosine
phosphatase. Protein-tyrosine phosphatase activity as-
sociated with the recombinant C-terminal domain of
FAK in vitro and could be coimmunoprecipitated with
both FAK and paxillin from lysates of chicken embryo
cells. However, the interaction with FAK appeared to be
indirect and mediated via paxillin. The protein-tyrosine
phosphatase was subsequently identified as protein-ty-
rosine phosphatase-PEST, a nonreceptor protein-tyro-
sine phosphatase. The C-terminal noncatalytic domain
of protein-tyrosine phosphatase-PEST directly bound to
paxillin in vitro. The association of both a protein-ty-
rosine kinase and a protein-tyrosine phosphatase with
paxillin suggests that paxillin may play a critical role in
the regulation of the phosphotyrosine content of pro-
teins in focal adhesions.
The integrins were originally identified as cell surface recep-
tors for extracellular matrix proteins. They participate in a
variety of cellular events, including adhesion, migration, inva-
sion, cytoskeleton organization, and the generation of cytoplas-
mic signals (1–3). Engagement of the integrins with the extra-
cellular matrix results in the formation of protein complexes
termed focal adhesions. In cultured fibroblasts, focal adhesions
are specialized structures that link the actin cytoskeleton to
extracellular matrix (4, 5). As a communication point between
extracellular matrix and the inside of cells, focal adhesions
perform both structural and signaling functions. One of the
most important events after the engagement of integrins with
their ligands is the rapid tyrosine phosphorylation of focal
adhesion-associated proteins (2, 3, 6).
Tyrosine phosphorylation of focal adhesion-associated pro-
teins may be controlled by the focal adhesion kinase (FAK),1 a
nonreceptor tyrosine kinase that localizes principally in focal
adhesions (2, 3, 6, 7). FAK is a major substrate for tyrosine
phosphorylation following integrin-dependent cell adhesion
and simultaneously becomes enzymatically activated (8–11).
Autophosphorylation of FAK creates a binding site for Src
family PTKs, and the assembly of this complex appears to be
important for tyrosine phosphorylation of focal adhesion-asso-
ciated proteins (12–14). p130cas and paxillin are, potentially,
downstream components of FAK signaling. They are colocal-
ized with FAK in focal adhesions, associate with FAK, and
become tyrosine-phosphorylated in coordination with FAK (9,
15–20). Tyrosine phosphorylation of p130cas and paxillin by
FAK and/or Src-like PTKs likely regulates the assembly of
signaling complexes in focal adhesions (13, 21–23).
The results of a number of pharmacological experiments
suggest that tyrosine phosphorylation may be involved in the
regulation of focal adhesion and stress fiber formation (9, 24–
27). Other evidence suggests that tyrosine phosphorylation
may not contribute to the assembly of focal adhesions. Micro-
injection of a dominant-negative FAK protein ablated tyrosine
phosphorylation in focal adhesions, yet the integrity of the focal
adhesions was unaffected, and new focal adhesions could still
form (28). Experiments using various strategies to perturb
normal FAK signaling suggest that FAK controls cell spread-
ing, the rate of focal adhesion formation, and cell migration (7,
28, 29). Recent evidence also suggests that FAK may function
in the transmission of a cell adhesion-dependent signal that is
required for cell survival (30, 31).
The phosphorylation of proteins on tyrosine can also be con-
trolled by PTPases (32). The role of PTPases in the regulation
of cytoskeletal structure and signaling via focal adhesions is
only beginning to be addressed. Several candidate PTPases
that may be involved in regulating tyrosine phosphorylation in
focal adhesions have been identified; they include LAR, PTP1B,
and PTP-PEST. LAR is a transmembrane PTPase expressed on
the cell surface as two noncovalently associated subunits de-
rived by cellular processing of a proprotein (33). LAR and an
associated protein LIP.1 can be localized to focal adhesions in
MCF7 cells (34). PTP1B and PTP-PEST are implicated in focal
adhesion signaling because both associate with p130cas, a ty-
rosine-phosphorylated focal adhesion-associated protein.
PTP1B directly associates with the SH3 domain of p130cas, and
overexpression of PTP1B leads to decreased tyrosine phospho-
rylation of p130cas (35). A proline-rich sequence of PTP-PEST
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can also bind the p130cas SH3 domain, but in addition, the
catalytic domain can directly interact with tyrosine-phospho-
rylated p130cas, and PTP-PEST may function to specifically
dephosphorylate p130cas (36, 37). Yersinia pseudotuberculosis,
which is a bacterial pathogen, encodes a PTPase that binds and
dephosphorylates both FAK and p130cas upon entry into cells
(38). This enzyme is essential for the virulence of a number of
Yersinia species (39). Thus, three cellular PTPases and one
bacterial PTPase have been implicated as potential regulators
of tyrosine phosphorylation of focal adhesion proteins.
In this study, we have tested the hypothesis that a PTPase
may be intimately associated with FAK. PTPase activity was
found to specifically associate with FAK, both in vitro and in
vivo. However, this interaction appeared to be indirect and was
in part mediated by the focal adhesion-associated protein pax-
illin. The PTPase was identified as PTP-PEST and was found
to directly bind to paxillin in vitro via its noncatalytic C-termi-
nal domain. The finding that paxillin associates with both a
PTK and a PTPase suggests novel models for the regulation of
tyrosine phosphorylation by the assembly of complexes con-
taining both enzymes.
MATERIALS AND METHODS
Cell Culture Techniques—Chicken embryo (CE) cells were prepared
and maintained as described (40). Swiss 3T3 cells were maintained in
Dulbecco’s modified Eagle’s medium-H 1 10% calf serum and Cos cells
in Dulbecco’s modified Eagle’s medium-H 1 10% fetal bovine serum.
Expression of Exogenous Proteins in CE and Cos Cells—The replica-
tion competent avian retroviral vector RCAS A (BH) (41) was used to
express wild type FAK, dl853–963, dl965–1012, and C-tagged FAK as
described previously (42, 43). For expression of PTP-PEST in Cos cells,
the murine cDNA was engineered to encode a C-terminal epitope tag
(KT3) using a PCR-based strategy. A 39 primer that created a BamHI
site and destroyed the termination codon was used, and the PCR prod-
uct was inserted into the plasmid pctag (43) (the BamHI site was
engineered so the PTP-PEST and KT3 codons of pctag were in frame).
The tagged cDNA was subcloned into pcDNA3 (Invitrogen, Carlsbad,
CA). To create a deletion mutant lacking the paxillin binding site, the
sequences encoding amino acids 1–300 were amplified by PCR using a
primer that created an EcoRI site at codon 300 that was in frame with
the EcoRI site at codon 494 of PTP-PEST. The PCR product was sub-
stituted for the sequences encoding amino acids 1–494 of epitope-tagged
PTP-PEST, then subcloned into pcDNA3. Cos cells were transiently
transfected with the PTP-PEST constructs using LipofectAMINE and the
protocol recommended by the manufacturer (Life Technologies, Inc.), and
the cells were lysed 48 h later.
In Gel Phosphatase Assay—Glutathione S-transferase (GST)-FER
(kindly provided by Dr. Shelton Earp, University of North Carolina-
Chapel Hill) was used as a PTK source for phosphorylation of the
substrate. One mg of poly(Glu,Tyr) was incubated with 10 mg GST-FER
in 500 ml of reaction buffer (200 mCi of [g-32P]ATP, 50 mM imidizole (pH
7.2), 10 mM dithiothreitol, 30 mM MgCl2, 1 mM MnCl2, 1 mM vanadate,
0.05% Triton X-100, 0.2 mM cold ATP, and 0.1% b-mercaptoethanol) for
4–6 h at room temperature with constant rotation as described (44).
The labeled poly(Glu,Tyr) was purified by trichloroacetic acid precipi-
tation and chromatography through a Sephadex G-50 column.
[g-32P]ATP-labeled poly(Glu,Tyr) (1 3 106 cpm) was incorporated into a
10% SDS-polyacrylamide gel prior to polymerization. After separating
the samples by electrophoresis, the SDS was removed, and the gel was
incubated in denaturing buffer (6 M guanidine chloride and 0.3% b-mer-
captoethanol) and then in renaturing buffer (50 mM Tris-HCl (pH 8.0),
1 mM EDTA, 0.04% Tween 20, and 0.3% b-mercaptoethanol) as de-
scribed (44). The gel was incubated in reaction buffer (50 mM Tris-HCl
(pH 8.0), 1 mM EDTA, 0.04% Tween 20, 0.3% b-mercaptoethanol, and 3
mM dithiothreitol) for 1 h and then in fresh buffer overnight. After
drying, the gel was exposed to x-ray film overnight.
Protein Analysis—Polyclonal antiserum directed against part of the
noncatalytic portion of PTP-PEST was generated in rabbits using a
trpE fusion protein containing amino acids 286–471 (49). A polyclonal
antiserum was used to recognize FAK (BC3; a gift of Tom Parsons,
University of Virginia), and commercially available monoclonal anti-
bodies were used to recognize paxillin and p130cas (Transduction Lab-
oratories, Lexington, KY). Cells were lysed in ice-cold modified radio-
immunoprecipation assay buffer (50 mM Tris-HCl [pH 7.3], 150 mM
NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.5% aprotinin, 1 mM phen-
ylmethylsulfonyl fluoride, 1.5 mM orthovanadate) or Triton X-100 buffer
(50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 10% glycerol,
0.5% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1.5 mM orthovana-
date). The protein concentration of the lysates was determined by the
bicinchoninic acid assay (Pierce). For in vitro phosphatase assays, the
cells were lysed in the absence of vanadate. For immunoprecipitations,
antibodies were incubated with 0.2–1 mg of cell lysate for 1 h on ice. The
immunecomplexes were recovered by incubation with protein A-Sepha-
rose beads (Pharmacia Biotech Inc.) or anti-mouse IgG-coupled agarose
beads (Sigma) for 1 h at 4 °C. After washing three times in lysis buffer
and twice in Tris-buffered saline (50 mM Tris-HCl (pH 7.5), 150 mM
NaCl), the immunecomplexes were dissociated by boiling in SDS sam-
ple buffer. The samples were analyzed using the in gel PTPase assay
(44) or by SDS-PAGE and Western blotting (50). For Western blotting,
primary antibodies were detected with horseradish peroxidase-conju-
gated secondary antibodies or protein A and ECL (Amersham Corp.).
Expression of GST Fusion Proteins—GST fusion proteins containing
the N- and C-terminal domains of FAK have been described (45).
Additional fusion constructs were engineered using PCR to amplify
C-terminal domain fragments of FAK, and the PCR products were
inserted into pGEX2TK (Pharmacia). GST-H-FAK contains codons
765–1052, GST-B-FAK contains codons 858–1052, and GST-S-FAK
contains codons 909–1052. Similarly, fragments of PTP-PEST were
amplified by PCR and subcloned into pGEX2TK. Fusion proteins con-
taining residues 1–301, 297–775, 441–775, and 297–494 were engi-
neered. The fusion proteins were expressed by incubation with 0.2 mM
isopropyl b-D-thiogalactopyranoside for 4–5 h at 37 °C, the bacteria
were lysed by sonication, and the fusion proteins were purified using
glutathione agarose.
Binding Experiments Using GST Fusion Proteins—One-half to one
mg of cell lysate was precleared with 10 mg of GST bound to glutathione
agarose beads for 60 min at 4 °C. The cleared supernatant was then
incubated with 0.1–1 mg of GST fusion protein immobilized on gluta-
thione agarose beads for 1 h at 4 °C. The beads were washed three times
in lysis buffer and twice in Tris-buffered saline. The bound proteins
were released by boiling in SDS sample buffer and analyzed by either
Western blotting or the in gel PTPase assay.
Far-Western Blotting—Six to 10 mg of purified GST fusion protein
was added to 40 ml of HMK buffer (20 mM Tris (pH 7.5), 100 mM NaCl,
12 mM MgCl2) containing 1 mM dithiothreitol, 50 units of protein kinase
A (Sigma) and 100 mCi of [g-32P]ATP (6000 Ci/mmol) (NEN Life Science
Products) (46, 47). After 45 min of incubation at room temperature, the
reaction was terminated with HMK stop buffer (10 mM sodium phos-
phate (pH 8.0), 10 mM sodium pyrophosphate, 10 mM EDTA). Radiola-
beled GST-PTP-PEST was separated from [g-32P]ATP by chromatogra-
phy on a Sephadex G-50 column. As described previously (46, 47),
protein samples were subjected to SDS-PAGE, transferred to nitrocel-
lulose, and denatured in buffer containing 6 M guanidine hydrochloride.
The samples were renatured by incubation in serial dilutions of dena-
turation buffer. Filters were washed and then blocked in 5% milk as
described (46, 47). Radioactive probe was added (to 6 3 106 cpm/ml) and
incubated for 8 h at 4 °C, and then the filter washed three times for 15
min and exposed to film.
RESULTS
Association of PTPase Activity with FAK in Vitro—Overex-
pression of FAK in CE cells does not induce tyrosine phospho-
rylation of cellular proteins unless the cells are treated with
vanadate, a PTPase inhibitor (22). These results suggest that
tyrosine phosphorylation of focal adhesion proteins may be
controlled by both FAK and an antagonistic, perhaps inti-
mately associated PTPase. To test whether FAK could bind a
PTPase, GST fusion proteins containing the N-terminal and
C-terminal noncatalytic domains of FAK were used to pull
down FAK-binding proteins from lysates of CE cells. The
PTPase activity associated with these fusion proteins was ex-
amined using an in gel PTPase assay. The GST-C-terminal
domain of FAK associated with four major bands of PTPase
activity with molecular masses of 97, 75–80 (a doublet), and 50
kDa (Fig. 1). It is not clear whether these are different PTPases
or represent breakdown products of the largest, 97-kDa
PTPase. The PTPase activities specifically bound to the C-
terminal domain of FAK because GST alone and GST-N-FAK
failed to associate with any detectable PTPase activity. A series
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of GST-fusion proteins containing smaller fragments of the
C-terminal domain of FAK was used to further map the FAK
sequences required for association with PTPase activity. The
GST-S-FAK construct contains only the focal adhesion target-
ing sequence, a 150-amino acid sequence that has been shown
to localize FAK to focal adhesions (42). Each of these constructs
associated with PTPase activity in vitro (Fig. 1). Analysis of the
fusion proteins by SDS-PAGE and Coomassie Blue staining
demonstrated that equivalent amounts of each fusion protein
were used in the analysis (Fig. 1B). These results indicate that
FAK can associate with PTPase activity in vitro and that the
focal adhesion targeting sequence is sufficient for association
with the PTPase.
Association of PTPase Activity with Paxillin—The FAK se-
quences required for association with PTPase activity in vitro
contain a binding site for paxillin, raising the possibility that
FAK associates with a PTPase(s) via its interaction with pax-
illin. To determine whether paxillin associates with PTPase
activity, paxillin immunecomplexes were analyzed using the in
gel PTPase assay. No PTPase activity was detected in control
immunoprecipitations lacking the primary antibody (Fig. 2).
The paxillin immunecomplex, however, exhibited PTPase ac-
tivity, and the molecular masses of the associated PTPase(s)
were 97, 75–80, and 50 kDa (Fig. 2). The pattern of PTPase
activities associated with GST-C-FAK was compared with the
PTPase pattern coimmunoprecipitated with paxillin and found
to be virtually identical (Fig. 2). Thus, paxillin associates with
PTPase activities in vivo, and the molecular masses of the
PTPase(s) are similar to those that associate with the C-termi-
nal domain of FAK in vitro.
Paxillin Mediates the Association between PTPase and
FAK—To determine whether paxillin was required for the as-
sociation of recombinant FAK with PTPase activity in vitro, a
clearing experiment was performed. Paxillin was cleared from
cell lysates by repeated immunoprecipitation. After three
rounds of immunodepletion using a paxillin monoclonal anti-
body, the amount of paxillin remaining in the lysate was un-
detectable by immunoprecipitation and immunoblotting (Fig.
3C). After each immunoprecipitation, the lysate was incubated
with GST-C-FAK, and the PTPase activity that associated with
FAK in vitro was measured using the in gel PTPase assay.
GST-C-FAK could no longer associate with PTPase activity
after paxillin was cleared from the lysate, whereas GST-C-FAK
bound PTPase activity in uncleared lysate (Fig. 3A). Following
four rounds of control immunoprecipitation using anti-mouse
IgG, the amount of PTPase that associated with GST-FAK was
undiminished (Fig. 3B). These results indicate that paxillin is
required for the association of FAK with PTPase activity in
vitro.
To determine whether paxillin mediates the association of
FAK with PTPase activity in vivo, mutants of FAK were ex-
pressed in CE cells, FAK was immunoprecipitated, and the
immunecomplexes were analyzed using the in gel PTPase as-
say. A 97-kDa PTPase was coimmunoprecipitated from CE
cells overexpressing FAK (Fig. 4A). Under these lysis condi-
tions, little PTPase activity coimmunoprecipitated with endog-
enous FAK (Fig. 4A, lane 1). However, under milder lysis
conditions, a 97-kDa PTPase could be coprecipitated with en-
dogenous FAK (Fig. 4B). The three FAK mutants analyzed, two
deletion mutants and a variant in which the C-terminal 13
residues are replaced with an epitope tag, each failed to coim-
munoprecipitate PTPase activity (Fig. 4A). Western blotting of
the immunecomplexes using BC3 antiserum indicated that
similar amounts of each mutant were recovered (Fig. 4A). Mu-
tants dl853–963 and dl965–1012 are defective in focal adhesion
targeting and paxillin binding (42, 47). Conversely, epitope-
tagged FAK is defective for paxillin binding but is correctly
localized to focal adhesions. Thus, paxillin binding correlates
with ability of FAK to coimmunoprecipitate PTPase activity
from cell lysates. These two results support the hypothesis that
FAK associates indirectly with PTPase activity and that pax-
illin may serve as an intermediary binding protein.
The 97-kDa PTPase Is PTP-PEST—To determine whether
PTP-PEST was the paxillin-associated PTPase, paxillin was
immunoprecipitated from CE cells or Swiss 3T3 cells, and the
immunecomplexes were probed with an anti-PTP-PEST anti-
body in a Western blot (Fig. 5A). PTP-PEST was detected in
paxillin immunecomplexes formed from each cell type. Control
immunecomplexes lacking the primary paxillin monoclonal an-
tibody did not contain PTP-PEST. Interestingly, the molecular
mass of PTP-PEST differed between species. Murine PTP-
PEST exhibited a molecular mass of 120 kDa, whereas avian
PTP-PEST was 97 kDa. Thus, the molecular mass of avian
PTP-PEST coincides with that of the major PTPase activity
that associates with paxillin. In addition, PTP-PEST was im-
munoprecipitated from CE cells and Swiss 3T3 cells, and the
immunecomplexes were Western blotted for paxillin. Control
immunoprecipitations using nonimmune serum contained no
paxillin, whereas PTP-PEST immunecomplexes contained de-
tectable paxillin (Fig. 5B). To confirm that the PTPase activity
FIG. 1. The focal adhesion targeting sequence of FAK binds
PTPase activity in vitro. A, lysates of CE cells were incubated with
GST alone (lane 1), GST-N-FAK (lane 2), GST-C-FAK (lane 3), GST-H-
FAK (lane 4), GST-B-FAK (lane 5), or GST-S-FAK (lane 6). The PT-
Pases associated with these GST fusion proteins were analyzed using
the in gel PTPase assay. B, the GST fusion proteins used in A were
analyzed by SDS-PAGE and Coomassie Blue staining. Lane 1, GST
alone; lane 2, GST-N-FAK; lane 3, GST-C-FAK; lane 4, GST-H-FAK;
lane 5, GST-B-FAK; lane 6, GST-S-FAK.
FIG. 2. PTPase activity coimmunoprecipitates with paxillin.
CE cells were lysed in modified radioimmunoprecipation assay buffer,
and the lysates were subjected to immunoprecipitation with secondary
antibody alone (Mock I.P., lane 1) or an antibody against paxillin
(paxillin I.P., lane 2). Lysates were also incubated with GST-C-FAK
(lane 3). The PTPases associated with each immunecomplex and with
GST-C-FAK were analyzed using the in gel phosphatase assay.
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originally detected by its association with recombinant FAK
was indeed PTP-PEST, CE and Swiss 3T3 cell lysates were
incubated with GST-C-FAK, and the bound proteins were blot-
ted for PTP-PEST. Indeed, PTP-PEST was found to be associ-
ated with GST-C-FAK (Fig. 5C). Despite the presence of
PTPase activity in FAK immunecomplexes (Fig. 4), PTP-PEST
could not be detected in FAK immunecomplexes by Western
blotting. This presumably reflects the low stoichiometry of
association with FAK. These results identify PTP-PEST as the
PTPase that coimmunoprecipitates with paxillin and associ-
ates with the C-terminal domain of FAK in vitro.
At first glance, comparing the amount of PTP-PEST in pax-
illin immunecomplexes with the amount immunoprecipitated
directly with the PTP-PEST antiserum, PTP-PEST appears to
associate with paxillin at a relatively high stoichiometry.
Therefore, experiments were performed to more carefully ex-
amine the stoichiometry of association. Serial paxillin immu-
noprecipitations were performed. Most of the paxillin was re-
covered in the first immunoprecipitation, some was recovered
in the second immunoprecipitation, and vanishingly small
amounts recovered in subsequent immunoprecipitations (Fig.
6C). Coimmunoprecipitating PTP-PEST was recovered pre-
dominantly in the first immunoprecipitation, although it was
detectable in the second immunoprecipitation as well (Fig. 6B).
To examine the stoichiometry of association, lysates were
Western blotted before and after paxillin was removed by im-
munoprecipitation. By comparison with serial dilutions of the
lysate prior to paxillin immunoprecipitation, it was estimated
that up to 50% of the PTP-PEST was removed upon immuno-
precipitation of paxillin (Fig. 6A). Control immunoprecipita-
tions did not detectably diminish the amount of PTP-PEST in
the lysate (Fig. 6A). In addition, the amount of PTP-PEST
recovered in paxillin immunoprecipitations was compared with
the amount of PTP-PEST in the lysate by Western blotting. In
Fig. 6B, the lysate loading control contains 50 mg of cell lysate
(lane 7), whereas paxillin was immunoprecipitated from 300 mg
of lysate. Thus, if equivalent signals were present in the lanes
containing lysate (lane 7) and the paxillin immunecomplex
(lanes 4–6), 15% of the PTP-PEST had been recovered in the
paxillin immunecomplexes. It is apparent that the amount of
PTP-PEST recovered in the paxillin immunecomplexes easily
exceeded 15% of that found in the lysate. It is therefore con-
cluded that PTP-PEST associates with paxillin with a rela-
tively high stoichiometry (a conservative estimate would be
20–25%).
The Noncatalytic Domain of PTP-PEST Binds Paxillin—To
map the paxillin binding site within PTP-PEST, fragments of
the PTPase were expressed as GST fusion proteins. The fusion
proteins were immobilized on glutathione beads and incubated
with CE cell lysates, and the cellular proteins that bound to
PTP-PEST were probed for paxillin by Western blotting. The
PTP-PEST 1–305 construct (containing the catalytic domain)
did not associate with paxillin (Fig. 7), whereas the PTP-PEST
297–775 construct did. Thus, the paxillin binding site resides in
the C-terminal noncatalytic domain of PTP-PEST. To further
narrow the binding site, two additional constructs were engi-
neered. PTP-PEST 441–775 exhibited no paxillin binding ac-
tivity, whereas PTP-PEST 297–494 bound paxillin as well as
the construct containing the entire C-terminal domain (Fig. 7).
Therefore, the paxillin binding site on PTP-PEST resides be-
tween residues 297 and 494. To determine whether this region
of PTP-PEST also mediated association with paxillin in vivo, a
deletion mutant lacking residues 300–494 was engineered.
Both wild type PTP-PEST and the mutant were epitope-tagged
using the KT3 tag and subcloned into pcDNA3. The constructs
were transiently transfected into Cos cells. Cells were lysed,
and exogenously expressed PTP-PEST was immunoprecipi-
tated with the antibody recognizing the tag. Each immunecom-
plex was probed for paxillin by Western blotting. Wild type
FIG. 3. Paxillin mediates the FAK/
PTPase association. A, CE cell lysates,
either before clearing (lane 1) or after
each of four consecutive paxillin immuno-
precipitations (lanes 2–5) were incubated
with GST-C-FAK, and bound PTPase ac-
tivity was detected using the in gel PTP-
ase assay. B, as in A, except that four
consecutive control immunoprecipitations
using secondary antibody alone were per-
formed. C, the immunecomplexes from
each of the four consecutive paxillin im-
munoprecipitations described in A were
analyzed by Western blotting for paxillin.
FIG. 4. C-terminal FAK mutants fail to bind PTPase activity in
vivo. A, CE cells (lane 1) or CE cells expressing wild type FAK (lane 2),
dl853–963 (lane 3), dl965–1012 (lane 4), or epitope-tagged FAK (lane 5)
were lysed in modified radioimmunoprecipation assay buffer and FAK
immunoprecipitated using BC3. The immunecomplexes were analyzed
using the in gel PTPase assay (top panel). Each immunecomplex was
also Western blotted using BC3 to verify that equivalent amounts of
wild type and mutant FAK were recovered (bottom panel). B, CE cells
were lysed in Triton X-100 lysis buffer. Endogenous FAK was immu-
noprecipitated using BC3, and the immunecomplex was analyzed using
the in gel PTPase assay (lane 2). Immunecomplexes formed using
nonimmune serum were used as the negative control (lane 1).
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PTP-PEST coimmunoprecipitated paxillin from Cos cells,
whereas control immunoprecipitations lacking the primary an-
tibody did not (Fig. 8). Cos cells express SV40 large T antigen,
which also contains the KT3 tag. Paxillin was not coimmuno-
precipitated with large T antigen, because KT3 immunopre-
cipitations from untransfected Cos cells did not contain detect-
able paxillin (Fig. 8). Thus, in transiently transfected Cos cells,
the paxillin/PTP-PEST interaction can be reconstituted. The
mutant PTP-PEST protein, dl300–494, was successfully ex-
pressed in Cos cells but failed to coimmunoprecipitate paxillin
(Fig. 8). Therefore, the region of PTP-PEST extending from
residue 297 to residue 494 is required for association with
paxillin both in vitro and in vivo.
PTP-PEST Binds Directly with Paxillin—A far-Western blot-
ting (also known as gel overlay) strategy was applied to deter-
FIG. 5. Paxillin coimmunoprecipitates with PTP-PEST. A, CE cell lysates (lanes 1, 3, and 5) or Swiss 3T3 cell lysates (lanes 2, 4, and 6) were
incubated with a control antibody (lanes 1 and 2), a paxillin monoclonal antibody (lanes 3 and 4), or the PTP-PEST antiserum (lanes 5 and 6). The
immunecomplexes were collected and analyzed by Western blotting using the PTP-PEST antiserum. B, CE cell lysates (lanes 1 and 2) or Swiss 3T3
cell lysates (lane 3) were subjected to immunoprecipitation with the PTP-PEST antiserum (lanes 2 and 3). The immunecomplexes were blotted with
a paxillin monoclonal antibody. A control immunoprecipitation was performed on the CE cell lysate (lane 1). C, lysates of CE cells (lanes 1 and 3)
or Swiss 3T3 cells (lanes 2 and 4) were either subjected to immunoprecipitation using the PTP-PEST antiserum (lanes 1 and 2) or incubated with
GST-C-FAK (lanes 3 and 4). The immunecomplexes and GST-C-FAK binding proteins were Western blotted with the PTP-PEST antiserum.
FIG. 6. Stoichiometry of PTP-PEST association with paxillin. Three sequential paxillin immunoprecipitations or control immunoprecipi-
tations were performed on 300 ml of CE cell lysate (at a concentration of 1 mg/ml). A, 50 ml of the supernatant following the paxillin
immunoprecipitations (lane 5) or control immunoprecipitations (lane 4) was analyzed by Western blotting for PTP-PEST. For comparison, 50 (lane
1), 25 (lane 2) or 12.5 (lane 3) ml of the original lysate was analyzed in parallel. B, each of the sequential paxillin immunecomplexes (lanes 4–6)
and the control immunecomplexes (lanes 1–3) was analyzed by Western blotting for PTP-PEST. As a control, 50 mg of lysate was analyzed in
parallel (lane 7). Because the immunoprecipitations were performed using 300 mg of lysate, the signal intensity of PTP-PEST in the paxillin
immunecomplexes equals the signal intensity in the lysate loading control if 15% of the PTP-PEST is recovered in the immunecomplex. C, the three
sequential paxillin immunecomplexes were probed for paxillin by Western blotting.
FIG. 7. Noncatalytic domain of PTP-PEST binds paxillin in
vitro. A, CE cell lysate was precleared with GST alone and then
incubated with GST (lane 2) or GST fusion proteins containing the
catalytic domain of PTP-PEST (1–305) (lane 3), the noncatalytic domain
of PTP-PEST (297–775) (lane 4), or fragments of the noncatalytic do-
main of PTP-PEST containing residues 441–775 (lane 5) or residues
297–494 (lane 6). Bound proteins were eluted with sample buffer and
analyzed by Western blotting for paxillin. CE cell lysate was directly
loaded in lane 1 as a control. B, the GST fusion proteins utilized in A
were analyzed by SDS-PAGE and Coomassie Blue staining to verify
that equivalent amounts of protein were used in the analysis.
FIG. 8. Noncatalytic domain of PTP-PEST bind paxillin in vivo.
A, Cos cells were transiently transfected with pcDNA constructs encod-
ing epitope-tagged PTP-PEST constructs. After 48 h, the cells were
lysed and PTP-PEST immunoprecipitated with the monoclonal anti-
body recognizing the KT3 epitope tag. Immunecomplexes formed from
mock-transfected cells (lane 2) or cells transfected with dl300–494 (lane
3) or with wild type PTP-PEST (WT, lane 4) were Western blotted for
paxillin. Lysate was loaded in lane 1 as a control. B, 50 mg of lysate from
mock-transfected (lane 1), wild type PTP-PEST transfected (WT, lane
2), or dl300–494-transfected (lane 3) cells were Western blotted with
monoclonal antibody KT3. The 90-kDa protein recognized by KT3 in the
mock and wild type samples is SV40 large T antigen, which is expressed
in Cos cells and contains the KT3 epitope. Note, however, that paxillin
is not coimmunoprecipitated with large T antigen (A, lane 2).
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mine whether PTP-PEST might directly bind paxillin. Paxillin
immunecomplexes were subjected to SDS-PAGE and trans-
ferred to nitrocellulose. The GST fusion protein containing
PTP-PEST sequences 297–494 was radiolabeled using
[g-32P]ATP and protein kinase A, which phosphorylates a site
at the junction of the GST and PTP-PEST polypeptides. This
fusion protein was used as the probe for the proteins immobi-
lized on the membrane. The PTP-PEST probe bound to two
proteins in the lane containing the paxillin immunecomplex
(Fig. 9). The 68-kDa protein is paxillin, and the 45-kDa protein
may be a paxillin-related species that can be immunoprecipi-
tated and detected in Western blots using paxillin monoclonal
antibodies (65). As controls, p130cas and FAK immunecom-
plexes were also analyzed. The PTP-PEST probe did not bind
any protein in the lane containing the FAK immunecomplex. It
did, however, bind to p130cas (Fig. 9). These results demon-
strate that a fragment of the noncatalytic domain of PTP-PEST
can directly bind to paxillin and p130cas in vitro.
DISCUSSION
In this study, we set out to test the hypothesis that FAK
intimately associated with a PTPase. Indeed, PTPase activity
did associate with FAK, both in vitro and in vivo. PTPase
activity was also detected in paxillin immunecomplexes. Two
lines of evidence suggest that the observed association of
PTPase activity with FAK was indirect. First, following immu-
nodepletion of paxillin from cell lysates, recombinant FAK was
unable to associate with PTPase activity in vitro. Second, mu-
tants of FAK that are defective for paxillin binding fail to
coimmunoprecipitate PTPase activity. PTP-PEST, a cytoplas-
mic member of a family of PTPases, was identified as the
paxillin binding PTPase. A region of the noncatalytic domain of
PTP-PEST contains the paxillin binding site and can directly
bind paxillin in vitro. Therefore, we favor a model in which
PTP-PEST can directly associate with paxillin and the small
amount of PTP-PEST associated with FAK does so indirectly,
via paxillin (Fig. 10).
PTP-PEST is a widely expressed PTPase belonging to the
PEST family of PTPases, which are characterized by proline,
glutamic acid, serine, and threonine rich sequences (48, 51).
Immunofluorescence and subcellular fractionation studies in-
dicate that PTP-PEST is localized to the cytoplasm of the cell
(48). The enzymatic activity of PTP-PEST can be repressed by
phosphorylation of serine residue 39 by either protein kinase A
or protein kinase C (52). The adaptor molecule Shc binds via its
phosphotyrosine binding (PTB) domain to a sequence in the
noncatalytic domain of PTP-PEST (NPLH) (53, 54). An abun-
dance of proline rich sequences in the noncatalytic domain of
PTP-PEST serve as docking sites for other signaling molecules.
Grb2 binds via its SH3 domain to the noncatalytic domain of
PTP-PEST, and through this interaction PTP-PEST can asso-
ciate with tyrosine-phosphorylated EGF receptor (48). The SH3
domain of the Csk PTK can also associate with a proline rich
sequence located distally, in the noncatalytic domain of PTP-
PEST (49). A distinct proline rich sequence in the noncatalytic
domain of PTP-PEST serves as a docking site for the SH3
domain of p130cas (37). Tyrosine-phosphorylated p130cas asso-
ciates tightly with the catalytic domain of “substrate trapping”
mutants of PTP-PEST and can be dephosphorylated by PTP-
PEST, suggesting that p130cas may be a specific substrate (36).
The SH3 domain mediated interaction between p130cas and
PTP-PEST may facilitate dephosphorylation of p130cas in vivo
(37).
In addition to these associated proteins, we have found that
paxillin directly binds to the noncatalytic domain of PTP-
PEST. Residues 297–494 of PTP-PEST contain both paxillin
and p130cas binding sites because this fragment of PTP-PEST
recognizes both proteins on a far-Western blot. A sequence
within this region (PPPKPPR) has been identified as the bind-
ing site for the SH3 domain of p130cas (37). The paxillin binding
site has not been further delineated; thus, the proximity of the
paxillin and p130cas binding sites is not known. Likewise, it
remains to be determined whether paxillin and p130cas can
simultaneously dock to PTP-PEST. It may be noteworthy that
paxillin and p130cas can be coimmunoprecipitated (55).2
Whether this observation is due to a direct interaction or is
mediated via an intermediate protein, e.g. PTP-PEST or FAK,
remains to be established. Coimmunoprecipitation and West-
ern blotting experiments suggest that more than 15% of the
cellular PTP-PEST is in complex with paxillin. This relatively
high stoichiometry of association between endogenous PTP-
PEST and endogenous paxillin presumably reflects the func-
tional importance of the interaction. The finding that PTP-
PEST associates with paxillin lends further credence to the
hypothesis that PTP-PEST may control signaling by dephos-
phorylation of focal adhesion-associated proteins.
2 Y. Shen and M. D. Schaller, unpublished observations.
FIG. 9. Noncatalytic domain of PTP-PEST binds directly to
paxillin. FAK immunecomplexes (lane 1), p130cas immunecomplexes
(lane 2) and paxillin immunecomplexes (lane 3) were resolved by SDS-
PAGE, transferred to nitrocellulose, and incubated with a radiolabeled
GST fusion protein containing residues 297–494 from PTP-PEST as a
probe.
FIG. 10. Model of PTP-PEST and focal adhesion signaling. PTP-
PEST binds directly to paxillin, and via paxillin, it may indirectly
associate with FAK. Through these interactions, PTP-PEST may be
directed to dephosphorylate paxillin, FAK, Src, or other focal adhesion-
associated substrates and function to regulate signaling at these sites.
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Presumably, the function of the paxillin/PTP-PEST-contain-
ing complex is to regulate the PTPase. Conceivably, paxillin
binding could regulate the enzymatic activity of the PTPase, in
either a stimulatory or inhibitory manner. A more likely sce-
nario is that paxillin regulates the accessibility of PTP-PEST to
its substrates. PTP-PEST may be targeted to focal adhesions,
the site of some of its substrates, e.g. p130cas, via its association
with paxillin. However, immunofluorescence experiments have
failed to reveal PTP-PEST in focal adhesions (48).2 This obser-
vation is somewhat surprising, given the relatively high stoi-
chiometry of association of PTP-PEST with paxillin. Perhaps
only a fraction of the cellular PTP-PEST resides in focal adhe-
sions or retargeting of PTP-PEST to focal adhesions may only
occur under certain conditions, e.g. immediately following cell
adhesion. Alternatively, paxillin may control the access of PTP-
PEST to its substrates by serving as a scaffold to recruit both
enzyme and its substrates into a complex.
The discovery that PTP-PEST binds paxillin suggests that
paxillin itself or other paxillin-binding partners might also
serve as PTP-PEST substrates. FAK is a paxillin-binding pro-
tein and therefore could also serve as a PTP-PEST substrate
(47, 56). An epitope-tagged FAK variant, which fails to bind
paxillin (47) and PTP-PEST, is remarkably normal in the reg-
ulation of its tyrosine phosphorylation.2 Thus, the recruitment
of PTP-PEST via paxillin may not be the exclusive mechanism
for the regulation of dephosphorylation of FAK. It is particu-
larly intriguing to speculate that PTP-PEST might be able to
dephosphorylate only a subset of the phosphorylation sites on
FAK or paxillin. One other interesting set of candidate sub-
strates are the Src family PTKs. Src can bind via its SH3
domain to paxillin (57), and both Src and Fyn can bind via their
SH2 domains to FAK (12, 58, 59). If PTP-PEST were brought
into the proximity of Src (or the FAK/Src complex) via paxillin,
the active conformation of Src might be stabilized by dephos-
phorylation of the negative site of regulation (60). This mech-
anism of activation is somewhat analogous to the activation of
the Src-like PTK, lck, in T cells by the CD45 PTPase (61, 62).
Alternatively, PTP-PEST might dephosphorylate tyrosine 416
of Src, which is the major site of autophosphorylation and a
positive regulatory site (60). Thus, models evoking PTP-PEST
as both a positive and negative regulator of Src can be
proposed.
The findings that PTP-PEST dephosphorylates p130cas and
associates with paxillin provides clues into how the enzyme
might be regulated. Stimuli that induce the dephosphorylation
of focal adhesion-associated proteins might enhance the activ-
ity of PTP-PEST. Alternatively, stimuli that induce tyrosine
phosphorylation of focal adhesion-associated proteins might
inhibit the activity of PTP-PEST. In this regard, it may be
noteworthy that integrin-dependent cell adhesion induces ty-
rosine phosphorylation of focal adhesion proteins and stimu-
lates the activity of protein kinase C (63, 64). Because serine
phosphorylation of PTP-PEST by either protein kinase C or
protein kinase A inhibits its activity (52), integrin-induced
serine phosphorylation of PTP-PEST by protein kinase C could
contribute to the elevation of phosphotyrosine levels following
cell adhesion.
Finally, it is intriguing that multimolecular complexes con-
taining a PTK (FAK), a PTPase (PTP-PEST), and paxillin can
be immunoprecipitated from cell lysates. We speculate that
paxillin may play a role in coordinating the tyrosine phospho-
rylation of focal adhesion associated proteins by recruiting
PTP-PEST and or FAK to their substrates. Thus, paxillin may
play a novel role in regulating tyrosine phosphorylation of
cellular proteins in both a spatial and a temporal fashion.
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